Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Niclosamide

FDA-approved product (tablet, chewable, oral), marketed as Niclocide.

Registered studies
35
Lab records
4
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Niclosamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Helminthiasis

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Salicylic acid derivatives
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P02DA01

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA48.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli20.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae6.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis47.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

35registered studies name this medicine, for any condition. See them below.

Experimental

  • M. tuberculosis: measured active in 4 of 4 lab records
Open Niclosamide in ChEMBL Registered studies below
Show the 4 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Niclosamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer

    NCT02532114 · start 2015-12-31

    Registered record
    Registry ID
    NCT02532114
    Conditions
    Castration Levels of Testosterone; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; Recurrent Prostate Carcinoma; Stage IV Prostate Adenocarcinoma
    Interventions
    Enzalutamide; Laboratory Biomarker Analysis; Niclosamide; Pharmacological Study
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-12-31
    Completion
    2017-11-30
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastration Levels of Testosterone; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; Recurrent Prostate Carcinoma +1 more
    InterventionEnzalutamide; Laboratory Biomarker Analysis; Niclosamide; Pharmacological Study
    PhasePhase 1
    Registry statusCompleted

  • Drug Trial to Investigate the Safety and Efficacy of Niclosamide Tablets in Patients With Metastases of a Colorectal Cancer Progressing After Therapy

    NCT02519582 · start 2015-08

    Registered record
    Registry ID
    NCT02519582
    Conditions
    Colorectal Cancer
    Interventions
    Niclosamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2015-08
    Completion
    2020-08
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    InterventionNiclosamide
    PhasePhase 2
    Registry statusUnknown

  • Targeted Screening for Taenia Solium Tapeworms

    NCT01296958 · start 2011-05

    Registered record
    Registry ID
    NCT01296958
    Conditions
    Taenia Solium Taeniasis
    Interventions
    Niclosamide; Community education campaign
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2011-05
    Completion
    2013-01
    Enrolment
    1,811

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTaenia Solium Taeniasis
    InterventionNiclosamide; Community education campaign
    PhaseNot applicable
    Registry statusCompleted

  • Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer Patients

    NCT01189903 · start 2011-01

    Registered record
    Registry ID
    NCT01189903
    Conditions
    Asian Colorectal Cancer Patients
    Interventions
    Regorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2011-01
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsian Colorectal Cancer Patients
    InterventionRegorafenib
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Mass Treatment T Solium Community Study

    NCT00138359 · start 2004-12

    Registered record
    Registry ID
    NCT00138359
    Conditions
    Intestinal Parasitism
    Interventions
    Niclosamide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2004-12
    Completion
    2005-01
    Enrolment
    4,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntestinal Parasitism
    InterventionNiclosamide
    PhaseNot applicable
    Registry statusTerminated